Effective pain control with equal short-term outcomes and patient satisfaction seen in patients who got non-opioid pain medication
Surgeons can ease their patients’ pain from common operations without prescribing opioids, and avoid the possibility of starting someone on a path to long-term use, a pair of new studies suggests.
Treating post-surgery pain with non-opioid pain medications such as ibuprofen or acetaminophen didn’t lead to higher pain levels or more serious issues during recovery, and didn’t dampen patients’ satisfaction with their care, according to new results from a study of more than 22,000 patients who had one of seven common operations at 70 hospitals.
The team behind the study has also produced a free, evidence-based guide for surgeons and other acute care providers, to help them treat patients’ pain without the risk of persistent use that opioids carry.
The new study is published in the Annals of Surgery by a team from Michigan Medicine, the University of Michigan’s academic medical center. They analyzed 2019 data from a Michigan-wide surgical care registry, and surveyed patients about their experience after they’d had a chance to recover.
Similar outcomes & experiences with and without opioids
The vast majority – 86% -- of the patients received a prescription for an opioid after they had hernia, gallbladder, appendix, bowel, thyroid or gynecological operations.
But when the researchers compared those patients’ experiences and survey responses with data from the 14% of patients who only got non-opioid painkiller prescriptions, they found little difference.
In all, an equal percentage -- 12% -- of both groups of patients had a major adverse event within 30 days of their initial operation. Specifically, there was no difference in complications, emergency department visits, or reoperations between groups. Patients not prescribed opioids were slightly more likely to be readmitted to the hospital, but rarely due to pain-related issues.
There was also no difference in the percentage who sought emergency care for pain.
The survey, carried out one month to three months after their operation, asked patients about their pain in the first seven days after they left the hospital, their satisfaction with their care, their quality of life and their level of regret about having surgery. Nearly 60% of patients completed it.
In all, 82% of both groups – patients who got an opioid prescription, and those who did not – said they were highly satisfied with their care. An even higher, but still equal, percentage of both groups (93%) said they had no regret about their surgery.
Those who didn’t receive opioid prescriptions were actually more likely to report no pain in the first week after surgery than those who did (12% vs 7%). The non-opioid patients were also slightly more likely to say they had the best possible quality of life after surgery (66% vs 63%).
“Opioids have been a routine part of post-surgical pain care for decades, but the risk that they could lead to persistent use has been clearly documented,” said Ryan Howard, M.D., the study’s lead author and a surgical resident at Michigan Medicine who is also a fellow at the Center for Healthcare Outcomes and Policy. “Perhaps it’s time to make them the exception, not the rule.”
Senior author Mark Bicket, M.D., Ph.D., a co-director of the Michigan Opioid Prescribing Engagement Network, or Michigan OPEN, is senior author of the new paper and a pain medicine specialist in the Department of Anesthesiology at Michigan Medicine.
He noted that 16% of the patients in the study were taking opioids on an ongoing basis before they had their operations. Long-term opioid use is known to increase risks from surgery.
“This study clearly shows no difference in pain, major adverse events or patient-centered outcomes when opioids aren’t prescribed,” he said. “The growing body of evidence about the risks of opioid medications to the patient, and to others who might misuse leftover pills from the patient’s prescriptions, has to be considered together with evidence about their relative effectiveness for pain control.”
Post-surgery persistent use and costs
Another new paper, led by fellow Michigan OPEN co-director Chad Brummett, M.D., uses national insurance claims data to document new persistent opioid use and costs of care for surgical patients who had not been taking opioids before their operations. It’s published in the June issue of the Journal of Managed Care and Specialty Pharmacy.
That study shows that between 4% and 7% of all patients who had surgery that required a hospital stay went on to fill opioid prescriptions months after their surgical pain should have faded, which the authors called new persistent opioid use. The same was true for between 1.5% and 6.4% of patients who had an outpatient operation. In this study, none of the patients had been filling opioid prescriptions before their operation.
These patients went on to have more hospital and emergency care in the following year, compared with those who didn’t fill a single opioid prescription immediately after their operation.
While some of the patients who didn’t fill an opioid prescription after surgery did go on to receive opioids for other reasons later in the follow-up year, those who started on opioids after surgery received five times more opioid prescriptions and much higher overall health care costs.
Prescribing guidelines and tools
The Michigan OPEN team has published research on the use of opioids for acute pain for several years, and used it to develop opioid prescribing recommendations for specific operations and procedures.
They’ve also created tools to help prescribers set patients’ expectations around pain control before they receive care. This can help patients understand how to use any opioids they might be prescribed wisely, and dispose of them safely.
The group’s new guidebook provides a comprehensive toolkit and additional information for prescribers and patients.
The Annals study used data from the Michigan Surgical Quality Collaborative, a collaborative quality initiative funded by Blue Cross Blue Shield of Michigan and led by co-author, Michigan-OPEN co-director and U-M surgery professor Michael Englesbe, M.D. Additional authors are Craig S. Brown, M.D., M.Sc., Yen-Ling Lai, MSPH, M.S.; Vidhya Gunaseelan, MBA, MS, MHA; Kao-Ping Chua, M.D., Ph.D.; Jennifer Waljee, M.D., M.P.H., M.S., and Englesbee and Brummett.
The other study includes multiple co-authors from IBM Watson Health and Heron Therapeutics and senior author Eric Sun, M.D., Ph.D., of Stanford University. It used data from national databases of people covered by private insurance, Medicare and Medicaid who had major operations between 2010 and 2017.
Bicket, Brummett, Englesbe, Chua and Waljee are members of the U-M Institute for Healthcare Policy and Innovation.
Funding for the study of post-operative outcomes was from the Blue Cross Blue Shield of Michigan Foundation, the Michigan Department of Health and Human Services and the National Institutes of Health.
Funding for the study of new persistent use and costs was provided by Heron Therapeutics. Brummett is a paid consultant to the company.